The psychoactive compound 5-methoxy-2-aminoindane (MEAI) is unique among psychedelics with therapeutic potential.  First, the drug could be self-administered. Second, it is patented, unlike psychedelics such as LSD, psilocybin, MDMA and ketamine. And while psychedelic drug developers tend to focus on indications such as depression, anxiety and post-traumatic stress disorder, MEAI could potentially treat alcoholism.  MEAI…